KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bausch Health Companies (BHC) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Bausch Health Companies (BHC) over the last 17 years, with Q3 2025 value amounting to $91.0 million.

  • Bausch Health Companies' Capital Expenditures rose 2816.9% to $91.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $411.0 million, marking a year-over-year increase of 2492.4%. This contributed to the annual value of $337.0 million for FY2024, which is 5674.42% up from last year.
  • As of Q3 2025, Bausch Health Companies' Capital Expenditures stood at $91.0 million, which was up 2816.9% from $99.0 million recorded in Q2 2025.
  • Bausch Health Companies' 5-year Capital Expenditures high stood at $115.0 million for Q1 2025, and its period low was $28.0 million during Q2 2023.
  • Its 5-year average for Capital Expenditures is $70.7 million, with a median of $66.0 million in 2021.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 4615.38% in 2023, then skyrocketed by 17857.14% in 2024.
  • Bausch Health Companies' Capital Expenditures (Quarter) stood at $78.0 million in 2021, then decreased by 15.38% to $66.0 million in 2022, then skyrocketed by 48.48% to $98.0 million in 2023, then grew by 8.16% to $106.0 million in 2024, then decreased by 14.15% to $91.0 million in 2025.
  • Its Capital Expenditures stands at $91.0 million for Q3 2025, versus $99.0 million for Q2 2025 and $115.0 million for Q1 2025.